One phase I/II trial of IT trastuzumab for patients with HER2-positive breast cancer patients demonstrated an mOS of 10.5 months for the HER2-positive breast cancer population with LM versus 3.3–4.4 months for historical controls [49,74]. Here, ERBB2 is linked to breast carcinoma.